TRexBio Employee Directory
Biotechnology ResearchCalifornia, United States51-200 Employees
TRexBio is a clinical-stage biotechnology company focused on discovering and developing immunoregulatory medicines based on tissue regulatory T cell biology. It emphasizes human tissue biology and uses computational biology tools as part of its Deep Biology platform to map tissue Treg behavior to disease processes and identify therapeutic targets. Its lead program, TRB-061, is a TNFR2-selective agonist in a Phase 1 trial for atopic dermatitis, designed to activate and expand effector Tregs in tissue to restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California, and employs about 51 to 200 people. The company has pursued collaborations and financing rounds, including a 2023 multi-year research collaboration with Eli Lilly and a Series B financing in 2024 (including an oversubscribed round of $84 million), with a $50 million extension announced in 2026.
1-888-653-2347 
support@leadiq.com 
